KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Treasury Shares: 2014-2025

Historic Treasury Shares for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to $12.2 million.

  • Aurinia Pharmaceuticals' Treasury Shares rose 258.82% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 258.82%. This contributed to the annual value of $8.0 million for FY2024, which is 2.29% up from last year.
  • Aurinia Pharmaceuticals' Treasury Shares amounted to $12.2 million in Q3 2025, which was up 8.93% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Treasury Shares registered a high of $14.8 million during Q2 2021, and its lowest value of $347,000 during Q4 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Treasury Shares had a median value of $7.9 million in 2023 and averaged $7.1 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first tumbled by 97.53% in 2021, then skyrocketed by 470.61% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Treasury Shares (Quarterly) stood at $347,000 in 2021, then skyrocketed by 470.61% to $2.0 million in 2022, then surged by 294.29% to $7.8 million in 2023, then rose by 2.29% to $8.0 million in 2024, then skyrocketed by 258.82% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $11.2 million for Q2 2025, and $5.8 million during Q1 2025.